Ozempic is a diabetes treatment
In the SUSTAIN 6 CV outcomes trial (CVOT), once-weekly semaglutide (0.5 or 1.0 mg) added to standard of care significantly reduced the occurrence of a first major adverse CV event (MACE: CV death, nonfatal myocardial infarction [MI], or nonfatal stroke) vs placebo over 2 years in 3297 subjects with T2D and high CV risk [12]
Discontinuation rates and dose escalation strategies Treatment discontinuation occurred in 7% of semaglutide recipients versus 5% with placebo
Its vital in the study of metabolic syndrome , pre-diabetes , and other conditions tied to glucose metabolism
At the weight management dose of 2.4 mg, semaglutide causes roughly 2.5 to 4 times more vomiting than tirzepatide at its highest dose
But instead of being indicated for chronic weight management, Rybelsus is approved to treat type 2 diabetes